MedTrace Logo

Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms

NCT04902833 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2026-05-19

No results posted yet for this study

Summary

This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.

Conditions

  • Pyruvate Kinase Deficiency
  • Pyruvate Kinase Deficiency Anemia
  • Hereditary Hemolytic Anemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasm
  • Clonal Myeloid Neoplasm
  • Myeloproliferative Neoplasm
  • Acute Myeloid Leukemia
  • Clonal Cytopenia of Undetermined Significance
  • Other Clonal Myeloid Neoplasm
  • Unexplained Coombs-negative Non-immune Hemolytic Anemia

Interventions

PROCEDURE

Blood Draw

Blood specimen 2-4 teaspoons

Sponsors & Collaborators

Principal Investigators

  • Hanny Al-Samkari, MD · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2026-02-01
Completion
2026-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04902833 on ClinicalTrials.gov